## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 5

### VALEANT PHARMACEUTICALS INTERNATIONAL

Form 5

February 10, 2005

<b>FORM</b>	5								OMB AF	PPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB Number:	3235-0362		
Check this box if with no longer subject				Washington, D.C. 20549						January 31, 2005		
to Section 1 Form 4 or F 5 obligation may continu	Form ANN as ale.		CATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Estimated average burden hours per response 1.0		
See Instruction 1(b). Form 3 Hole Reported Form 4 Transactions Reported	Filed purs dings Section 17(a	) of the Pu	ıblic Uti	o(a) of the So lity Holding restment Co	g Compa	ny A	ct of 19					
1. Name and Ad THURMAN	ldress of Reporting F RANDY	S	Symbol Issuer						Reporting Person(s) to			
			VALEANT PHARMACEUTICALS INTERNATIONAL [VRX]					(Check all applicable)				
(Last)	(First) (M	(1	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)  12/31/2004				title 10% Owner Other (specify below)					
3300 HYLAND AVENUE												
	Filed(Month/Day/Year)							int/Group Reporting k applicable line)				
COSTA MESA, CA 92626  _X_ Form Filed by One Reporting Person Form Filed by More than One Reporting Person												
(City)	(State) (	Zip)	Table	I - Non-Deriv	vative Sec	urities	s Acquire	ed, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	saction Date 2A. Deemed  //Day/Year) Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and	Ownership Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Amount	or (D)	Price	4)				
Dividend Equivalent Rights	01/28/2004	Â		A4	38 (1)	A	\$ 23.87	141	D	Â		
Dividend Equivalent Rights	04/28/2004	Â		A4	36 (1)	A	\$ 25.53	177	D	Â		
Dividend Equivalent Rights	07/28/2004	Â		A4	89 (1)	A	\$ 17.13	266	D	Â		

#### Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 5

Dividend Equivalent 10/27/2004 Â A4  $66\frac{(1)}{2}$  A 8 24.59 332 D Â Rights

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270

(9-02)

9. of D

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)
				(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

THURMAN RANDY

3300 HYLAND AVENUE Â X Â Â

COSTA MESA, CAÂ 92626

## **Signatures**

By: Michelle May For: Randy H.
Thurman
02/04/2005

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The dividend equivalent rights accrued on phantom stock that are subject to all the terms and conditions of the underlying phantom stock to which they relate.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2